HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nu Skin

This article was originally published in The Rose Sheet

Executive Summary

Weaker than expected results in the U.S., mainland China and Japan in the third quarter have prompted the company to lower revenue expectations, projecting sales will be up 2% to $290 mil., versus earlier estimates of $298 mil.-$303 mil., Nu Skin reports Oct. 4. Earnings per share during the quarter will be in the range of $.24-$.26, compared to earlier projections of $.29-$.30. Based on Q3 expectations, Nu Skin is revising its fourth quarter revenue guidance to $300 mil.-$306 mil., "assuming an exchange rate of 112 yen to the dollar, which would result in annual revenue increasing 5% to approximately $1.2 bil. for 2005," firm adds...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013418

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel